Skin Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Skin Cancer Information Center has current, evidence-based information for you. Get the facts about skin cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing skin cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Skin Cancer Community is the leading Social Media Application for Skin Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Erivedge recently approved for metastatic basal cell carcinoma and sonidegib demonstrating promising results in clinical trials. OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine
Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition... Sonidegib Demonstrates Benefit in Advanced Basal Cell Skin Cancer in Phase II Trial
Promising drug for patients with advanced basal cell carcinoma.
Cancer and its treatment can come with a variety of complications, some more serious... Summer Sun Safety Tips
By Justin Piasecki, MD As summer arrives each year, I’m often asked about the balance... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Skin Cancer Management
By Diana Price When Dr. Perry Robbins founded the Skin Cancer Foundation in 1979,... Jack & Jill Late Stage Cancer Foundation
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after...
Skin Cancer Clinical Trials
REFMAL31 – A STUDY TO DETERMINE THE BIOEQUIVALENCE OF AN ORAL FORMULATION OF TOPOTECAN CONTAINING THE DRUG SUBSTANCE MANUFACTURED BY NEW PROCESS RELATIVE TO THE CURRENT STUDY FORMULATION OF TOPOTECAN IN PATIENTS WITH ADVANCED SOLID TUMORS
REFMAL32 – AN OPEN-LABEL, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF MULTIPLE DOSES OF GW572016 TO EXAMINE THE INHIBITION OF EGFR/ERBB-2 PHOSPHORYLATION IN CANCER PATIENTS WITH SOLID TUMORS
REFMAL33 – A PHASE I TRIAL OF WEEKLY AMONAFIDE (AMF)IN PATIENTS WITH ADVANCED, SOLID TUMORS